Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Būtiski notikumi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2007-12-10 14:33:31 |
Versijas komentārs | |
Teksts |
From this 10th of December, JSC Grindeks begins to offer Rispaxol® - the qualitative new generation medicine for the treatment of schizophrenia. This medicine will be included in the List of reimbursable medical products of Grindeks keeps observing continuously the tendencies on pharmaceutical market, responding to them quickly and actively to offer consumers new medicines necessary to meet their needs. „I am satisfied with our ability to offer to Latvian market high quality effective product manufactured by domestic producer, and complying with all and any modern international requirements and quality standards. The new medicine will be effective measure in struggling against disastrous disease; furthermore, we have found a possibility to offer it to the state for the most beneficial price. Introduction of Rispaxol® shows Grindeks as a company having obtained considerable achievement in extending its product range,” pointed Jānis Romanovskis, Chairman of the Board of Grindeks. Perspective development and promotion of generics which will have been carrying out on the market soon after expiration of a patent covering original products, is the one of strategic directions of the Grindeks’s new products development. Rispaxol® is bioequivalent* to the original product Risperidonum, which had been task-oriented created to fight effectively against schizophrenia – one of the gravest mental diseases. According to the World Health Organization statistical data, schizophrenia is one of the most prevalent insanities, and 1% of the population of the world is affected with it, regardless of economic conditions in the state, irrespective of continent and climate. The incidence of this disease, diagnosed in Grindeks has intended to start a promotion of Rispaxol® in JSC Grindeks is the leading pharmaceutical company in Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia as well as ten representative offices. Products of the company are exported to more than 40 countries. Main markets are the Baltic States, Russia and CIS countries, Japan, USA. Grindeks shares are listed in the Official List of Riga Stock Exchange. Manager of the Communications Department of JSC Grindeks Phone: Mob. phone: * If two or more similar dosage forms of a drug reach the general circulation at the same relative rate and the same relative extent, they are bioequivalent ** Sources – The Business Activity Report of State Mental Health Agency and data base of Central Statistics Board. |
Pielikumi |
|